Citations with the tag: PHARMACEUTICAL ethics
Results 1 - 50
- Beware the counterpunch.
Lafferty, Elaine // Time International (South Pacific Edition); 04/28/97, Issue 17, p69
Looks at how some pharmacists believe they should have the right to refuse to fill a prescription if they have ethical, moral or religious objections to the prescription. The example of John Boling's refusal to fill Michelle Crider's prescription for birth control pills; The policy of the...
- Drug companies criticised for exaggeration.
Ferriman, Annabel // BMJ: British Medical Journal (International Edition); 04/10/99, Vol. 318 Issue 7189, p962
Reports on the increasing number of complaints against pharmaceutical companies in Great Britain. Report from the Prescription Medicines Code of Practice Authority; Companies involved in the complaints; Overview of the criticisms.
- A tough addiction to cure.
Sloane, Todd // Modern Healthcare; 5/20/2002, Vol. 32 Issue 20, p23
Editorial. Discusses the need of doctors and drugmakers in the U.S. to find a more ethical way of doing business. Usual ethical guideline for taking anything other than information from sources; Ethics policy unveiled by the Pharmaceutical Research and Manufacturers of America in response to...
- Pharmaceutical Promotion and First Amendment Rights.
Troy, Daniel E.; Gottlieb, Scott // New England Journal of Medicine; 7/31/2008, Vol. 359 Issue 5, p536
A letter to the editor is presented in response to the article "Pharmaceutical Promotion to Physicians and First Amendment Rights" by A. S. Kesselheim and J. Avorn in the April 17, 2008 issue.
- Pharmaceutical Promotion and First Amendment Rights.
Kesselheim, Aaron S.; Avorn, Jerry // New England Journal of Medicine; 7/31/2008, Vol. 359 Issue 5, p536
Aaron S. Kesselheim and Jerry Avorn respond to a letter to the editor about their article "Pharmaceutical Promotion to Physicians and First Amendment Rights" in the April 17, 2008 issue.
- The Ethics of Pharmaceutical Benefit Management.
Burton, Stephan L.; Randel, Lauren; Titlow, Karen; Emanuel, Ezekiel J. // Health Affairs; Sep/Oct2001, Vol. 20 Issue 5, p150
Focuses on the ethics of pharmaceutical benefit management and drug costs control in the United States. Values of pharmacy benefit management; Effect of direct control on the resources of drug use; Impact of increasing burden in prescription drug costs on medical services coverage for...
- Drug store chains get into marketing mix.
Mortland, Shannon // Crain's Cleveland Business; 7/8/2002, Vol. 23 Issue 27, p29
Reports the business status of the pharmaceutical companies in the U.S. Involvement of the pharmacy chains in marketing; Target consumers of the companies; Existence of ethical issues among doctors.
- GPs 'misled' by rep's claim of PCG backing.
Mortland, Shannon // GP: General Practitioner; 9/16/2002, p18
Reports that representative of pharmaceutical company Trinity has violated the Prescription Medicines Code of Practice by giving the misleading impression that she was working with local primary care group.
- Ethical hot spots.
Snyder, Karyn // Drug Topics; 1/20/97, Vol. 141 Issue 2, p41
Presents ethical dilemmas that may be encountered in the practice of pharmacy and relevant commentaries from professional ethicists. Includes assistance in a physician-assisted suicide; Selling of tobacco; Dispensation of abortion drugs if they were legal; Withholding treatment from a patient...
- Ethical considerations concerning treatment allocation in drug development trials.
Senn, S // Statistical Methods in Medical Research; Oct2002, Vol. 11 Issue 5, p403
It is claimed that much of the opposition to placebos is based on the misunderstanding that their use implies the withholding of effective treatments. It is also argued that the ethical feasibility of a trial must be judged by comparing the likely prognosis of patients in the trial to their...
- Pfizer reprimanded over misleading cox-2 claims.
Nairon, Nerys // Pulse; 6/18/2005, Vol. 65 Issue 24, p12
Reports that the Association of the British Pharmaceutical Industry (ABPI) has reprimanded Pfizer Inc. for misleading general practitioners on the cardiovascular safety of celecoxib in Great Britain. Number of breaches committed by the company in relation to the industry code; Assessment of the...
- Ethics and Compliance Environment.
Nairon, Nerys // Pharmaceutical Representative; Jul2010, Vol. 40 Issue 7, p26
The article discusses the ethics and compliance environment in the U.S. pharmaceutical industry. It identifies the overarching goals of most regulatory and ethical mandates. It describes the role of various regulatory agencies and of the pharmaceutical industry in establishing and enforcing...
- New APhA officials, ethics code.
Nairon, Nerys // Drug Topics; 11/21/94, Vol. 138 Issue 22, p8
Reports that Calvin H. Knowlton has been chosen as American Pharmaceutical Association (APhA) 1995-96 president-elect. Line-up of the elected board of trustees; Approval of a new code of ethics for pharmacists; Appointments to the house of delegates.
- Roche faces charges over Taq patent claim.
Abbott, Alison // Nature; 8/22/1996, Vol. 382 Issue 6593, p660
Reports that Swiss pharmaceuticals company Hoffman-La Roche and United States biotechnology company Cetus face charges of intent to mislead the United States Patent and Trademark Office (PTO) by claiming to have found a unique enzyme called Taq DNA polymerase. The relationship between Hoffman-...
- Pharmacovigilance in Nepal: Whose baby is it anyway?
Shankar, P. R. // Australasian Medical Journal; 2013, Vol. 6 Issue 3, p132
A letter to the editor is presented in response to the article "Do Community pharmacists in Nepal have a role in adverse drug reaction reporting systems?" that was published in the previous issue of the journal.
- Don't throttle patient care in the new push for privacy.
Frederick, James // Drug Store News; 1/12/98, Vol. 20 Issue 1, pCP4
Editorial. Focuses on issues related to patient privacy in the United States. Implications of legislation that would protect patients' prescription and medical records from unauthorized disclosure of non-medical uses on retail pharmacy; Pressure on the US Congress to enact patient privacy...
Smith, Brian // International Journal of Medical Marketing; Apr2004, Vol. 4 Issue 2, p185
Scans the research papers for medical marketers covering broader topics relevant to pharmaceuticals industry. Parallel import as a threat to medical marketers; Importance of a cross-functional working; Similarities between the medical markets and financial services industry; Particular...
- Merchandising Cigarettes in Pharmacies: A San Francisco Survey.
Schroeder, Steven A.; Showstack, Jonathen A. // American Journal of Public Health; May78, Vol. 68 Issue 5, p494
The article focuses on the study on the prevalence of cigarette merchandising in pharmacies in San Francisco, California. A random sample of 100 pharmacies were gathered with data regarding the sale of cigarettes, the place where cigarettes are placed in conformity to pharmaceutical...
- Madison hospitals say no to food, gifts, trinkets.
Thompson, Cheryl A. // American Journal of Health-System Pharmacy; 12/15/2006, Vol. 63 Issue 24, p2438
The article reports on the adoption of a citywide policy in Madison, Wisconsin that prohibits drug company representatives to bring gifts to hospitals and clinics. The move aims to curb the behavior of drug company representatives. The exception to the ban and the immediate results of the...
Boerma, G.J.M.; Arntzenius, A.C.; Crompton, Graham K.; Williams, H.; Lancaster, W.M.; Symmers, W.St.C.; Kelleher, Philip C.; Smith, Carol J.P.; Fumarola, D.; Mann, J.I.; Reid, Alistair; Hart, Julian Tudor; Davidson, N.McD.; Goodspeed, A.H.; Todd, John W.; Mathers, James; Morris, Ian; Darbyshire, Myles // British Medical Journal; 11/3/1979, Vol. 2 Issue 6198, p1140
Presents several letters inquiring about topics related to medicine. Sources of errors affecting the reliability of clinical laboratory data; Examination of ethics applied to the promotion of ketotifen by Sandoz Products Ltd.; Clarification regarding the position of the Scottish case on babesiosis.
- Professional Codes versus External Enforcement: Chinese and Australian Norm-Setting in Pharmaceutical Ethics Compared.
DU Liping // Cross-Cultural Communication; 2011, Vol. 7 Issue 4, p1
This paper examines how norms are introduced and implemented in the production and trade of medicines in China and Australia. Through a discussion of the status of the pharmaceutical profession in these two countries, it argues that in China the propagation of professional standards and the...
- Pride and prejudice.
Spence, Des // BMJ: British Medical Journal (Overseas & Retired Doctors Edition; 4/25/2009, Vol. 338 Issue 7701, p1018
In this article the author discusses the moral and ethical issues that are associated with relationships which exist between drug firm representatives and physicians in Great Britain. He is critical of the British government's failure to act on the relationships. He suggests that the if the...
- Pharmaceutical sales representatives and physicians:...
Peppin, John F. // Journal of Medicine & Philosophy; Feb96, Vol. 21 Issue 1, p83
Examines the controversy surrounding the relationship between Pharmaceutical Sales Representatives (PRS) with physicians in the United States. Appearance of PSR's in 1850; Steady growth of PSRs since 1850; Circumstances surrounding debate; Ethical issues invovled in the relationships between...
- Minding Morals.
Park, Jeannette // Pharmaceutical Executive; Mar2006 Supplement, Vol. 26, p6
The article reflects on the morals which may be the bases in planning an event or meeting of the pharmaceutical industry in the U.S. According to Mike McGraw, president of Tneve Co., all activities of a product-launch event should have same message. One should be memorable by disseminating the...
- A Futile Defence of Bland: A Reply to Andrew McGee.
Keown, John // Medical Law Review; Sep2005, Vol. 13 Issue 3, p393
The article presents a debate that serves as a response to the statement of Andrew McGee which strongly holds that there is a cogent and defensible distinction between intended and merely foreseen consequences. It notes that McGee criticises the failure test to distinguish intended from foreseen...
- The Ethics of Pharma.
Keown, John // Pharmaceutical Executive; Dec2004, Vol. 24 Issue 12, p88
Interviews several pharmaceutical executives about the ethics associated with the pharmaceutical industry in the U.S. Role of ethics in corporate decision making; Outlook on the obligation of the industry to make medications affordable to everyone; Policies and programs pharmaceutical companies...
- PHARMACEUTICAL DRUG PROMOTION IN PAKISTAN: ISSUES IN ETHICAL AND NON-ETHICAL PRACTICES.
AHMED, RIZWAN RAHEEM; SAEED, AHMAD // Interdisciplinary Journal of Contemporary Research in Business; Aug2012, Vol. 4 Issue 4, p149
This study not only evaluates the responsible variables for the unethical pharmaceutical marketing practices but also compare who is more responsible for these unethical pharmaceutical marketing practices in Pakistan. This study also examines, who has initiated these unethical pharmaceutical...
- The Naked Patient.
Futter, Billy // South African Pharmaceutical Journal; 2013, Vol. 80 Issue 4, p48
The article reports on the need of improving rational use of medicine and the role of pharmacists in it. It mentions that pharmacists enhance the better use of medicines as they prevent the irrational use of medicines. It informs about a programme that train patients on how to buy and use...
- Your Drug Dollars at Work.
Elliott, Justin // Mother Jones; Sep/Oct2008, Vol. 33 Issue 5, p54
The article reports on the results of a study that was conducted by two Canadian researchers and which was concerned with expenditures of the U.S. pharmaceutical industry. The researchers found that the pharmaceutical industry of the U.S. has an annual research budget of $31.5 billion, spends...
- Regional considerations in the splitting of tablets.
Rindone, Joseph P. // Drugs & Therapy Perspectives; Jul2003, Vol. 19 Issue 7, p25
Presents information on the practice of tablet splitting in the U.S. Debate over the ethics of tablet splitting; Percentage of savings that can be accumulated from tablet splitting in cases wherein pricing differences are the same.
- Drug bazaar.
Fischman, Joshua; Melton, Marissa // U.S. News & World Report; 06/21/99, Vol. 126 Issue 24, p58
Describes the ease with which illegal or prescription drugs can be purchased over the Internet, and many problems with such action. Danger of self-prescribing drugs; Specific drugs available, such as drugs like Codipront and Contugesic which contain the highly addictive codeine; Other drugs and...
- The Geographical Distribution of Leadership in Globalized Clinical Trials.
Hoekman, Jarno; Frenken, Koen; de Zeeuw, Dick; Heerspink, Hiddo Lambers // PLoS Clinical Trials; Oct2012, Vol. 7 Issue 10, p1
Background: Pharmaceutical trials are mainly initiated by sponsors and investigators in the United States, Western Europe and Japan. However, more and more patients are enrolled in Central and Eastern Europe, Latin America and Asia. The involvement of patients in new geographical settings...
- Negotiating the moral maze.
Halstead, Jan // Nursing Standard; 6/17/2009, Vol. 23 Issue 41, p28
The article presents an overview of moral and ethical dilemmas that people in the medical community face as a result of receiving gifts, trips and meals from representatives of the pharmaceutical industry and medical supplies industry. The author suggests that while most members of the medical...
- Drugs Over Dotage.
Brenchley, Fred // Bulletin with Newsweek; 12/29/98-01/05/99, Vol. 117 Issue 6155, p114
Focuses on the popularity of `lifestyle' drug solutions in Australia to such ailments as baldness and impotence for an aging population anxious to preserve its youth and health. How the success of drugs such as Viagra and Propecia has opened up avenues for drug companies and chemists to flout...
- AAPS and FDA Announce Signing of a Cooperative R&D Agreement.
Brenchley, Fred // Pharmaceutical Processing; Jan2008, Vol. 24 Issue 1, p34
The article reports that the American Association of Pharmaceutical Scientists (AAPS) has signed the Cooperative Research and Development Agreement (CRADA) with the U.S. Food & Drug Administration (FDA). Under the terms of the agreement, AAPS and the FDA will look to advance current researh by...
- NEWS BRIEFS.
Brenchley, Fred // MondayMorning; 2/16/2009, Vol. 17 Issue 6, p5
The article offers news briefs related to pharmaceutical industry. Pfizer Inc. said that it will begin to disclose most payments made to doctors and other U.S. healthcare professionals by next year. Takeda Pharmaceutical Co. and Xoma Ltd. said that they would expand their partnership to give...
- Direct-to-Consumer Advertising For Erectile Dysfunction Drugs.
Karlowicz, Karen A. // Urologic Nursing; Jul/Aug2009, Vol. 29 Issue 4, p214
The author reflects on direct to consumer advertising which is concerned with erectile dysfunction drugs. She suggests that many people have problems with open discussions of sexual health problems. She argues that urologic nurses should have discussions with pharmaceutical representatives about...
- Fraud office prosecution over fixing price of generic drugs collapses.
Dyer, Clare // BMJ: British Medical Journal (International Edition); 7/19/2008, Vol. 337 Issue 7662, p131
The article focuses on the resolution of a British legal case involving five drug companies and nine directors who had been accused of a multimillion dollar conspiracy to swindle Great Britain's National Health Service by fixing prices of generic drugs. After an eight year legal battle which...
- Spam medicine.
Spence, Des // BMJ: British Medical Journal (International Edition); 7/19/2008, Vol. 337 Issue 7662, p178
The author reflects on emails that are used by pharmaceutical companies to market drugs for various medical conditions, some of which may not even be legitimate medical problems. He suggests that the purpose of the emails is to pollute and poison the stream of people's lives. He argues that the...
- Direct to consumer advertising of prescription drugs.
Mintzes, Barbara // BMJ: British Medical Journal (International Edition); 9/6/2008, Vol. 337 Issue 7669, p526
The author reflects on direct-to-consumer advertising of prescription drugs. She suggests that even forms of direct-to-consumer drug advertising which occurs across borders can cause harm. She argues that research and debates have suggested that the advertising causes harm to women and has...
- New Ethics for Big Pharma.
Gaudio, Thomas // njbiz; 1/15/2007, Vol. 20 Issue 3, p3
The article reports that the International Federation of Pharmaceutical Manufacturers & Associations has revised its code of ethics to add a provision on improper product marketing by companies to doctors and other health care professionals. The revised code prohibits pharmaceutical...
- The story of Vioxx�no pain and a lot of gain: ethical concerns regarding conduct of the pharmaceutical industry.
Cahana, Alex; Mauron, Alexandre // Journal of Anesthesia; 2006, Vol. 20 Issue 4, p348
The article discusses ethical concerns regarding the conduct of the pharmaceutical industry in the light of the development and withdrawal of non-steroidal anti-inflammatory drug Vioxx. The growing concerns over the safety and efficacy of Vioxx has forced its manufacturers to withdraw it from...
- Legal tactics to delay launch of generic drugs cost Europe �3bn.
Jack, Andrew // BMJ: British Medical Journal (International Edition); 12/6/2008, Vol. 337 Issue 7682, p1311
The article focuses on the publication of a report on the practices of the pharmaceutical industry in Europe that was published by the European Commission's Competition Directorate. The report focuses on widespread ethically questionable legal tactics that the pharmaceutical industry has used to...
- Anthropology and the Pharmaceutical Nexus.
van der Geest, Sjaak // Anthropological Quarterly; Spring2006, Vol. 79 Issue 2, p303
This article reviews the book "Global Pharmaceuticals: Ethics, Markets, Practices," by Adriana Petryna, Andrew Lakoff and Arthur Kleinman.
- Recent Publications on Medications and Pharmacy.
Sterling, Jacyntha // Hospital Pharmacy; May2008, Vol. 43 Issue 5, p429
The article offers information on several publications on pharmacy. It discusses a study on various interventions aimed at promoting institutional safety at hospitals. One research revealed that patient with myocardial infarction (MI) were more likely to adhere to beta-blocker treatment if they...
- Drug industry weakens US bill about disclosure of gifts to doctors.
Burton, Bob // BMJ: British Medical Journal (International Edition); 6/7/2008, Vol. 336 Issue 7656, p1268
The article focuses on the weakening of a proposed legislative bill about the disclosure of gifts to doctors in the U.S. The weakening, which was the result of successful lobbying by the pharmaceutical industry, will lesson the impact of the legislation, which was developed in an effort to...
- Publicidad y promoci�n de medicamentos: regulaciones y grado de acatamiento en cinco pa�ses de Am�rica Latina.
Vacca, Claudia; Vargas, Claudia; Ca��s, Mart�n; Reveiz, Ludovic // Pan American Journal of Public Health; Feb2011, Vol. 29 Issue 2, p76
No abstract available.
- Are Drug Companies Living Up to Their Human Rights Responsibilities? Moving Toward Assessment.
Gruskin, Sofia; Raad, Zyde // PLoS Clinical Trials; Sep2010, Vol. 7 Issue 9, p1
In this article, the authors stress the need for more assessment on whether pharmaceutical companies are fulfilling their human rights responsibilities. It says that some of them adopt corporate social responsibility while others prioritize patents over access to essential medicines (EM). Under...
- Are Drug Companies Living Up to Their Human Rights Responsibilities? The Perspective of the Former United Nations Special Rapporteur (2002-2008).
Hunt, Paul; Khosla, Rajat // PLoS Clinical Trials; Sep2010, Vol. 7 Issue 9, Special section p1
The article reflects on two reports on human rights guidelines for pharmaceutical companies on access to medicines and human rights responsibilities, and the policies of GlaxoSmithKline (GSK) on the issue prepared by the former United Nations (UN) Special Rapporteur on the right to the highest...
- Drug Companies Should Be Held More Accountable for Their Human Rights Responsibilities.
Hunt, Paul; Khosla, Rajat // PLoS Clinical Trials; Sep2010, Vol. 7 Issue 9, Special section p1
The authors reflect on the need for governments to held pharmaceutical companies liable for their human rights responsibilities as discussed in three articles in the same issue. First, they summarize the requirements set in the report "Human Rights Guidelines for Pharmaceutical Companies"...